New study tests 3D mapping to boost heart ablation precision

NCT ID NCT07014423

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using a 3D electroanatomic mapping system (FARAVIEW) during pulsed field ablation helps create more precise lesions in the pulmonary veins of people with atrial fibrillation. Thirty-two participants were randomly assigned to receive ablation with or without the 3D mapping. The main goal was to see if the ablation lesions were more evenly shaped with mapping, and whether fewer extra ablations were needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pulsed field ablation with or without FARAVIEW 3D mapping software
What this could lead to
If successful, this could show that 3D mapping helps doctors deliver more precise ablation lesions, potentially reducing the need for extra procedures in atrial fibrillation treatment.
What could go wrong
This is a small, early-stage study with only 32 participants, so results may not apply to all patients. The benefit of 3D mapping may be small or not clinically meaningful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.